SignatureFD’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $73.4K | Buy |
1,544
+42
| +3% | +$2.21K | ﹤0.01% | 1502 |
|
|
2025
Q4 | $78.8K | Sell |
1,502
-70
| -4% | -$4.19K | ﹤0.01% | 1423 |
|
|
2025
Q3 | $102K | Sell |
1,572
-64
| -4% | -$3.67K | ﹤0.01% | 1291 |
|
|
2025
Q2 | $79.6K | Sell |
1,636
-39
| -2% | -$1.51K | ﹤0.01% | 1347 |
|
|
2025
Q1 | $57K | Sell |
1,675
-82
| -5% | -$3.48K | ﹤0.01% | 1500 |
|
|
2024
Q4 | $69.2K | Sell |
1,757
-160
| -8% | -$7.55K | ﹤0.01% | 1411 |
|
|
2024
Q3 | $90.1K | Sell |
1,917
-28
| -1% | -$1.42K | ﹤0.01% | 1266 |
|
|
2024
Q2 | $105K | Sell |
1,945
-15
| -0.8% | -$868 | ﹤0.01% | 1139 |
|
|
2024
Q1 | $134K | Buy |
1,960
+58
| +3% | +$4.15K | ﹤0.01% | 1032 |
|
|
2023
Q4 | $119K | Sell |
1,902
-222
| -10% | -$12.3K | ﹤0.01% | 1009 |
|
|
2023
Q3 | $96.4K | Buy |
2,124
+236
| +13% | +$12.2K | ﹤0.01% | 1075 |
|
|
2023
Q2 | $106K | Sell |
1,888
-17
| -0.9% | -$965 | ﹤0.01% | 1028 |
|
|
2023
Q1 | $86.2K | Buy |
1,905
+244
| +15% | +$11.9K | ﹤0.01% | 1119 |
|
|
2022
Q4 | $67.5K | Sell |
1,661
-364
| -18% | -$19.3K | ﹤0.01% | 1201 |
|
|
2022
Q3 | $132K | Buy |
2,025
+253
| +14% | +$18.3K | ﹤0.01% | 827 |
|
|
2022
Q2 | $108K | Sell |
1,772
-37
| -2% | -$2.17K | ﹤0.01% | 950 |
|
|
2022
Q1 | $114K | Buy |
1,809
+1,069
| +144% | +$67.1K | ﹤0.01% | 973 |
|
|
2021
Q4 | $56K | Sell |
740
-195
| -21% | -$17K | ﹤0.01% | 1278 |
|
|
2021
Q3 | $105K | Sell |
935
-1,435
| -61% | -$180K | ﹤0.01% | 947 |
|
|
2021
Q2 | $384K | Sell |
2,370
-90
| -4% | -$10.9K | 0.02% | 444 |
|
|
2021
Q1 | $300K | Buy |
2,460
+1,545
| +169% | +$233K | 0.01% | 451 |
|
|
2020
Q4 | $140K | Buy |
915
+115
| +14% | +$13.6K | 0.01% | 652 |
|
|
2020
Q3 | $67K | Sell |
800
-65
| -8% | -$5.77K | ﹤0.01% | 854 |
|
|
2020
Q2 | $64K | Sell |
865
-75
| -8% | -$4.38K | ﹤0.01% | 857 |
|
|
2020
Q1 | $40K | Buy |
940
+275
| +41% | +$14.2K | ﹤0.01% | 970 |
|
|
2019
Q4 | $41K | Hold |
665
| – | – | ﹤0.01% | 1037 |
|
|
2019
Q3 | $27K | Hold |
665
| – | – | ﹤0.01% | 1123 |
|
|
2019
Q2 | $31K | Sell |
665
-20
| -3% | -$799 | ﹤0.01% | 1054 |
|
|
2019
Q1 | $24K | Buy |
685
+85
| +14% | +$2.94K | ﹤0.01% | 1120 |
|
|
2018
Q4 | $17K | Sell |
600
-1,700
| -74% | -$59.1K | ﹤0.01% | 1190 |
|
|
2018
Q3 | $102K | Sell |
2,300
-50
| -2% | -$2.62K | 0.01% | 630 |
|
|
2018
Q2 | $138K | Buy |
2,350
+1,300
| +124% | +$74.1K | 0.02% | 503 |
|
|
2018
Q1 | $48K | Buy |
+1,050
| New | +$43.3K | 0.01% | 749 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
SignatureFD's CRSP Position: Q1 2026 in Review
SignatureFD increased its CRISPR Therapeutics (CRSP) stake by 2.8% in Q1 2026, buying an estimated $2.21K and bringing the position to 1,544 shares worth $73.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1502.
SignatureFD first reported a position in CRSP in Q1 2018 and has held it in 33 quarters since. The position peaked at $384K in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- SignatureFD held 1,544 shares of CRISPR Therapeutics worth $73.4K as of Q1 2026.
- SignatureFD bought 42 CRISPR Therapeutics shares in Q1 2026, an estimated $2.21K.
- CRISPR Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #1502 holding.
- SignatureFD first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 33 quarters since.
- SignatureFD's CRISPR Therapeutics position peaked at $384K in Q2 2021.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.